{"id":"aflibercept-folfiri","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"30-40","effect":"Nausea"},{"rate":"20-30","effect":"Abdominal pain"},{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Proteinuria"},{"rate":"5-10","effect":"Hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept is a VEGF trap that sequesters vascular endothelial growth factor, preventing new blood vessel formation that tumors depend on for growth. FOLFIRI is a combination chemotherapy regimen (5-fluorouracil, leucovorin, and irinotecan) that damages DNA and inhibits topoisomerase I. Together, they provide dual anti-angiogenic and cytotoxic activity against colorectal cancer.","oneSentence":"Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:32.643Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with FOLFIRI)"},{"name":"Second-line treatment of metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT05178745","phase":"","title":"Resection Observatory","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-07","conditions":"Metastatic Colorectal Cancer, Colorectal Neoplasms","enrollment":140},{"nctId":"NCT03730558","phase":"","title":"ZETA : Prospective Observational Study","status":"COMPLETED","sponsor":"Recherche clinique","startDate":"2017-11-08","conditions":"Metastatic Colon Cancer","enrollment":120},{"nctId":"NCT04392479","phase":"PHASE3","title":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","status":"UNKNOWN","sponsor":"Hôpital Franco-Britannique-Fondation Cognacq-Jay","startDate":"2020-09-02","conditions":"Cancer Colorectal, Metastasis","enrollment":202},{"nctId":"NCT03279289","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2017-10-25","conditions":"Metastatic Colorectal Cancer","enrollment":170},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT02173990","phase":"PHASE2","title":"Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2014-07","conditions":"Metastatic Colorectal Cancer","enrollment":40},{"nctId":"NCT02181556","phase":"PHASE2","title":"Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2014-10","conditions":"Metastatic Colorectal Cancer","enrollment":41},{"nctId":"NCT04810585","phase":"PHASE4","title":"Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-04-20","conditions":"Recurrent or Metastatic Colorectal Cancer","enrollment":153},{"nctId":"NCT04397601","phase":"","title":"Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2020-05-11","conditions":"Metastatic Colorectal Cancer","enrollment":220},{"nctId":"NCT04252456","phase":"NA","title":"Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status","status":"UNKNOWN","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2018-04-23","conditions":"Advanced Colorectal Cancer","enrollment":150},{"nctId":"NCT02331927","phase":"PHASE2","title":"PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"University of Ulm","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":150},{"nctId":"NCT02970916","phase":"PHASE2","title":"Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2016-11","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT02624726","phase":"PHASE2","title":"Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment","status":"UNKNOWN","sponsor":"Hellenic Oncology Research Group","startDate":"2016-01","conditions":"Metastatic Colorectal Cancer","enrollment":31},{"nctId":"NCT01571284","phase":"PHASE3","title":"Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05-30","conditions":"Colorectal Cancer Metastatic","enrollment":781},{"nctId":"NCT02129257","phase":"PHASE2","title":"Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2014-05-26","conditions":"Metastatic Colorectal Cancer","enrollment":73},{"nctId":"NCT01882868","phase":"PHASE2","title":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-07","conditions":"Colorectal Cancer Metastatic","enrollment":62},{"nctId":"NCT02046538","phase":"PHASE2","title":"Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2014-02","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum","enrollment":""},{"nctId":"NCT01670721","phase":"PHASE3","title":"Colorectal Cancer Metastatic","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Colorectal Cancer Metastatic","enrollment":175},{"nctId":"NCT02045030","phase":"PHASE2","title":"Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2014-01","conditions":"Metastatic Colorectal Cancer","enrollment":14},{"nctId":"NCT01661270","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Colorectal Cancer Metastatic","enrollment":332},{"nctId":"NCT01930552","phase":"PHASE1","title":"A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-09","conditions":"Neoplasm Malignant","enrollment":20},{"nctId":"NCT01941173","phase":"NA","title":"Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2014-01","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":""},{"nctId":"NCT01754272","phase":"","title":"A Non-Interventional Follow-Up to the VELOUR Study - Translational Research","status":"UNKNOWN","sponsor":"KU Leuven","startDate":"2012-01","conditions":"Metastatic Colorectal Cancer","enrollment":1226},{"nctId":"NCT00921661","phase":"PHASE1","title":"Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Colorectal Neoplasms, Neoplasm Metastasis","enrollment":16},{"nctId":"NCT00561470","phase":"PHASE3","title":"Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-11","conditions":"Colorectal Neoplasms, Neoplasm Metastasis","enrollment":1226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["aflibercept","FOLFIRI"],"phase":"marketed","status":"active","brandName":"aflibercept + FOLFIRI","genericName":"aflibercept + FOLFIRI","companyName":"CR-CSSS Champlain-Charles-Le Moyne","companyId":"cr-csss-champlain-charles-le-moyne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan. Used for Metastatic colorectal cancer (in combination with FOLFIRI), Second-line treatment of metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}